SEATTLE, Sept. 19 /PRNewswire/ -- Icogen Corporation announced today that it has received notice of award for another Phase I Small Business Innovative Research (SBIR) grant from the National Institute of Health (NIH). The grant is to fund the first application of Icogen's new proprietary, high-throughput proteomics screening technology, ISOPLeC(TM), to identify an effector protein as the basis for a new Sickle Cell Anemia therapy. Icogen has received $4.6 million in NIH grant funding since 1996.
``The NIH scientific peer review process for evaluating SBIR grant applications constitutes an important validation of our innovative, break- through peptide screening technology,'' states Fredrick S. Hagen, Ph.D., Icogen's founder and President. ``Our ISOPLeC(TM) technology enables the rapid screening of large peptide libraries to efficiently identify which peptide(s) out of a 100 million or more has potential as the basis of a new treatment for the specific disease(s) being targeted.'' Dr. Hagen notes that although Icogen's ISOPLeC(TM) technology was originally developed for its internal use, it has a broad application in screening the products of the Human Genome Project to identify new lead compound targets for treating disease and genetic disorders. Icogen is now seeking corporate partners to capitalize on the exciting potential of its new screening capability.
Icogen is a Seattle-based, privately held company founded by Dr. Hagen in 1995 to identify and commercialize proteins and protein effectors as the basis of new treatments for human diseases. The notification of NIH funding for the first drug discovery application of Icogen's new ISOPLeC(TM) technology for Sickle Cell Anemia represents a significant milestone in the company's evolution... |
